ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Pliant Therapeutics Inc

Pliant Therapeutics Inc (PLRX)

14.90
0.35
(2.41%)
Closed March 29 04:00PM
14.90
0.00
(0.00%)
After Hours: 04:01PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
14.90
Bid
13.98
Ask
15.79
Volume
292,430
14.38 Day's Range 14.96
12.605 52 Week Range 30.85
Market Cap
Previous Close
14.55
Open
14.69
Last Trade
1
@
15.2
Last Trade Time
Financial Volume
$ 4,303,562
VWAP
14.7166
Average Volume (3m)
407,366
Shares Outstanding
60,239,176
Dividend Yield
-
PE Ratio
-5.56
Earnings Per Share (EPS)
-2.68
Revenue
1.58M
Net Profit
-161.34M

About Pliant Therapeutics Inc

Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis. Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dover, Delaware, USA
Founded
1970
Pliant Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PLRX. The last closing price for Pliant Therapeutics was $14.55. Over the last year, Pliant Therapeutics shares have traded in a share price range of $ 12.605 to $ 30.85.

Pliant Therapeutics currently has 60,239,176 shares outstanding. The market capitalization of Pliant Therapeutics is $896.96 million. Pliant Therapeutics has a price to earnings ratio (PE ratio) of -5.56.

PLRX Latest News

Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference

Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq:...

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly shorten bexotegrast’s time to Phase 3 data Upsized Oxford Finance debt...

Form S-8 - Securities to be offered to employees in employee benefit plans

 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549__________________________________________FORM S-8REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF...

Form 8-K - Current report

0001746473FALSE00017464732024-02-272024-02-27 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549__________________________________________FORM...

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results

Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment continues in BEACON-IPF, a Phase 2b trial in patients with IPF SOUTH SAN...

Pliant Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G   UNDER THE SECURITIES EXCHANGE ACT OF 1934   (Amendment No...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.3-1.9736842105315.215.6314.0732692514.60309331CS
4-2.19-12.814511410217.0917.58514.0736137815.14131868CS
12-3.5-19.021739130418.419.6213.440736616.42675997CS
26-1.74-10.456730769216.6419.6212.60545748915.86274CS
52-11.62-43.815987933626.5230.8512.60562509619.00235273CS
156-24.54-62.221095334739.44403.96554535420.74081474CS
260-7.6-33.777777777822.543.923.96545775721.28753312CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

PLRX Discussion

View Posts

Your Recent History

Delayed Upgrade Clock